Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies

References

• Keating M J, Chiorazzi N, Messmer B, Damle R N, Allen S L, Rai K R, et al. Biology and treatment of chronic lymphocytic leukaemia. Haematol (Am Soc Hematol Educ Prog) 2003; 1: 153–175
   Google Scholar
• Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88
   PubMed Web of Science ®Google Scholar
• Doney K C, Chauncey T, Appelbaum F R, for the Seattle Bone Marrow Transplant Team. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukaemia. Bone Marrow Transplant 2002; 29: 817–823
   PubMed Web of Science ®Google Scholar
• Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukaemia. Leukaemia 2002; 16: 985–992
   PubMed Web of Science ®Google Scholar
• Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579–590
   PubMed Web of Science ®Google Scholar
• Reid D C. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001; 112: 874–887
   PubMed Web of Science ®Google Scholar
• Timmerman J M, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507–529
   PubMed Web of Science ®Google Scholar
• Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001; 24: 66–78
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka A K, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451–6458
   PubMed Web of Science ®Google Scholar
• Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669–1678
   PubMed Web of Science ®Google Scholar
• Vuillier F, Maloum K, Thomas E K, Jouanne C, Dighiero G, Scott-Algara D. Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 831–844
   PubMed Web of Science ®Google Scholar
• Timmerman J M, Czerwinski D K, Davis T A, Hsu F J, Benike C, Hao Z M, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–1526
   PubMed Web of Science ®Google Scholar
• Goddard R V, Prentice A G, Copplestone J A, Kaminski E R. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin Exp Immunol 2003; 131: 82–89
   PubMed Web of Science ®Google Scholar
• Muller M R, Tsakou G, Grunebach F, Schmidt S M, Brossart P. Induction of chronic lymphocytic leukaemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 2004; 103: 1763–1769
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Rezvany M R, Virving L, Choudhury A, Rabbani H, Osterborg A, et al. Dendritic cells loaded with apoptotic tumor cells induce a stronger T-cell response than dendritic cell-tumor hybrids in B-CLL. Leukaemia 2003; 17: 894–899
   PubMed Web of Science ®Google Scholar
• Goddard R V, Prentice A G, Copplestone J A, Kaminski E R. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumor cell lysate. Clin Exp Immunol 2001; 126: 16–28
   PubMed Web of Science ®Google Scholar
• Ribas A, Bui L A, Butterfield L H, Vollmer C M, Jilani S M, Dissette V B, et al. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res 1999; 19: 1165–1170
   Google Scholar
• Zitvogel L, Mayordomo J I, Tjandrawan T, DeLeo A B, Clarke M R, Lotze M T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87–97
   PubMed Web of Science ®Google Scholar
• Nair S K, Snyder D, Rouse B T, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70: 706–715
   PubMed Web of Science ®Google Scholar
• Storkus W J, Zeh H J, III, Salter R D, Lotze M T. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993; 14: 94–103
   PubMed Web of Science ®Google Scholar
• Hsu F J, Caspar C B, Czerwinski D, Kwak L W, Liles T M, Syrengelas A, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood 1997; 89: 3129–3135
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Steinman R M, Sapp M, Desai H, Fossella C, Krasovsky J, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104: 173–180
   PubMed Web of Science ®Google Scholar
• Berger T G, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Meth 2002; 268: 131–140
   PubMed Web of Science ®Google Scholar
• Probst H C, McCoy K, Okazaki T, Honjo T, van den Broek M. Reting dendritic cells induce CD8+ T cell tolerance through PD-1 and CTLA-4. Nature Immunol 2005; 6: 280–286
   PubMed Web of Science ®Google Scholar
• Gad M, Kristensen N N, Kury E, Claesson M H. Characterization of T-regulatory cells, induced by immature dendritic cells, which inhibit enteroantigen-reactive colitis-inducing T-cell responses in vitro and in vivo. Immunology 2004; 113: 499–508
   PubMed Web of Science ®Google Scholar
• Weng W K, Czerwinski D, Timmerman J, Hsu F J, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: 4717–4724
   PubMed Web of Science ®Google Scholar